Estrogen and SERM neuroprotection in animal models of Parkinson's disease

Molecular and Cellular Endocrinology

Volumn 290, Issue 1-2, 2008, Pages 60-69

  Morissette, Marc ^a,b   Sweidi, Sara Al ^a,b   Callier, Sophie ^a,b   Di Paolo, Thérèse ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Androgen; Dehydroepiandrosterone; Estradiol; Estrogen receptor; Progesterone; SERMs

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 1,3,5 TRIS(4 HYDROXYPHENYL) 4 PROPYLPYRAZOLE; 16ALPHA ETHYL 21 HYDROXY 19 NORPREGN 4 ENE 3,20 DIONE; 17ALPHA ESTRADIOL; 2,3 BIS(4 HYDROXYPHENYL)PROPIONITRILE; ANDROSTANOLONE; ANDROSTENEDIOL; CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; DOPAMINE; ESTRADIOL; ESTRIOL; ESTROGEN DERIVATIVE; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; ESTRONE; GLYCOGEN SYNTHASE KINASE 3BETA; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PRASTERONE; PROGESTERONE; PROPIONITRILE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TESTOSTERONE;

ARTICLE; BREAST CANCER; COGNITIVE DEFECT; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG ABUSE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; HUMAN; MORBIDITY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OSTEOPOROSIS; PARKINSON DISEASE; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; DISEASE MODELS, ANIMAL; ESTROGENS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 47849098033     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.04.008     Document Type: Article

References (179)

1. Bae Y.H., Hwang J.Y., Kim Y.H., and Koh J.Y. Anti-oxidative neuroprotection by estrogens in mouse cortical cultures. J. Korean Med. Sci. 15 (2000) 327-336
2. Baldereschi M., Di Carlo A., Rocca W.A., Vanni P., Maggi S., Perissinotto E., Grigoletto F., Amaducci L., and Inzitari D. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 55 (2000) 1358-1363
3. Barrett-Connor E., Slone S., Greendale G., Kritz-Silverstein D., Espeland M., Johnson S.R., Waclawiw M., and Fineberg S.E. The Postmenopausal estrogen/progestin interventions study: primary outcomes in adherent women. Maturitas 27 (1997) 261-274
4. Baulieu E.E. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology 23 (1998) 963-987
5. Baulieu E.E., and Robel P. Dehydroepiandrosterone (DHEA) and dehydroepiandrosterone sulfate (DHEAS) as neuroactive neurosteroids. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 4089-4091
6. Becker J.B. Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol. Biochem. Behav. 64 (1999) 803-812
7. Bedard P., Langelier P., and Villeneuve A. Oestrogens and extrapyramidal system [letter]. Lancet 2 (1977) 1367-1368
8. Behl C. Oestrogen as a neuroprotective hormone. Nat. Rev. Neurosci. 3 (2002) 433-442
9. Behl C., Skutella T., Lezoualc'h F., Post A., Widmann M., Newton C.J., and Holsboer F. Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol. Pharmacol. 51 (1997) 535-541
10. Belanger A., Candas B., Dupont A., Cusan L., Diamond P., Gomez J.L., and Labrie F. Changes in serum concentrations of conjugated and unconjugated steroids in 40- to 80-year-old men. J. Clin. Endocrinol. Metab. 79 (1994) 1086-1090
11. Benedetti M.D., Maraganore D.M., Bower J.H., McDonnell S.K., Peterson B.J., Ahlskog J.E., Schaid D.J., and Rocca W.A. Hysterectomy, menopause, and estrogen use preceding Parkinson's disease: an exploratory case-control study. Mov. Disord. 16 (2001) 830-837
12. Bezard E., Gross C.E., Fournier M.C., Dovero S., Bloch B., and Jaber M. Absence of MPTP-induced neuronal death in mice lacking the dopamine transporter. Exp. Neurol. 155 (1999) 268-273
13. Bi R., Broutman G., Foy M.R., Thompson R.F., and Baudry M. The tyrosine kinase and mitogen-activated protein kinase pathways mediate multiple effects of estrogen in hippocampus. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 3602-3607
14. Bialek M., Zaremba P., Borowicz K.K., and Czuczwar S.J. Neuroprotective role of testosterone in the nervous system. Pol. J. Pharmacol. 56 (2004) 509-518
15. Biglan K.M., and Ravina B. Neuroprotection in Parkinson's disease: an elusive goal. Semin. Neurol. 27 (2007) 106-112
16. Bjornstrom L., and Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 19 (2005) 833-842
17. Blanchet P.J., Fang J., Hyland K., Arnold L.A., Mouradian M.M., and Chase T.N. Short-term effects of high-dose 17beta-estradiol in postmenopausal PD patients: a crossover study. Neurology 53 (1999) 91-95
18. Blandini F. Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?. CNS Drug Rev. 11 (2005) 183-194
19. Bower J.H., Maraganore D.M., McDonnell S.K., and Rocca W.A. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 52 (1999) 1214-1220
20. Brailoiu E., Dun S.L., Brailoiu G.C., Mizuo K., Sklar L.A., Oprea T.I., Prossnitz E.R., and Dun N.J. Distribution and characterization of estrogen receptor G protein-coupled receptor 30 in the rat central nervous system. J. Endocrinol. 193 (2007) 311-321
21. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., Anderson M.J., Arden K.C., Blenis J., and Greenberg M.E. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96 (1999) 857-868
22. Budziszewska B., Leskiewicz M., Kubera M., Jaworska-Feil L., Kajta M., and Lason W. Estrone, but not 17 beta-estradiol, attenuates kainate-induced seizures and toxicity in male mice. Exp. Clin. Endocrinol. Diab. 109 (2001) 168-173
23. Bywood P.T., and Johnson S.M. Dendrite loss is a characteristic early indicator of toxin-induced neurodegeneration in rat midbrain slices. Exp. Neurol. 161 (2000) 306-316
24. Callier S., Morissette M., Grandbois M., Pelaprat D., and Di Paolo T. Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse 41 (2001) 131-138
25. Callier S., Morissette M., Grandbois M., and Di Paolo T. Stereospecific prevention by 17beta-estradiol of MPTP-induced dopamine depletion in mice. Synapse 37 (2000) 245-251
26. Cardona-Gomez G.P., Mendez P., DonCarlos L.L., Azcoitia I., and Garcia-Segura L.M. Interactions of estrogens and insulin-like growth factor-I in the brain: implications for neuroprotection. Brain Res. Brain Res. Rev. 37 (2001) 320-334
27. Cardona-Gomez G.P., Mendez P., DonCarlos L.L., Azcoitia I., and Garcia-Segura L.M. Interactions of estrogen and insulin-like growth factor-I in the brain: molecular mechanisms and functional implications. J. Steroid Biochem. Mol. Biol. 83 (2002) 211-217
28. Carswell H.V., Macrae I.M., Gallagher L., Harrop E., and Horsburgh K.J. Neuroprotection by a selective estrogen receptor beta agonist in a mouse model of global ischemia. Am. J. Physiol. Heart Circ. Physiol. 287 (2004) H1501-1504
29. Chen G., Bower K.A., Ma C., Fang S., Thiele C.J., and Luo J. Glycogen synthase kinase 3beta (GSK3beta) mediates 6-hydroxydopamine-induced neuronal death. FASEB J. 18 (2004) 1162-1164
30. Chen Z.J., Parent L., and Maniatis T. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell 84 (1996) 853-862
31. Chong Z.Z., Li F., and Maiese K. Activating Akt and the brain's resources to drive cellular survival and prevent inflammatory injury. Histol. Histopathol. 20 (2005) 299-315
32. Cole G.M., and Frautschy S.A. The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's disease. Exp. Gerontol. 42 (2007) 10-21
33. Collier T.J., Dung Ling Z., Carvey P.M., Fletcher-Turner A., Yurek D.M., Sladek Jr. J.R., and Kordower J.H. Striatal trophic factor activity in aging monkeys with unilateral MPTP-induced parkinsonism. Exp. Neurol. 191 Suppl. 1 (2005) S60-67
34. Currie L.J., Harrison M.B., Trugman J.M., Bennett J.P., and Wooten G.F. Postmenopausal estrogen use affects risk for Parkinson disease. Arch. Neurol. 61 (2004) 886-888
35. Cyr M., Calon F., Morissette M., and Di Paolo T. Estrogenic modulation of brain activity: implications for schizophrenia and Parkinson's disease. J. Psychiatry Neurosci. 27 (2002) 12-27
36. Cyr M., Calon F., Morissette M., Grandbois M., Di Paolo T., and Callier S. Drugs with estrogen-like potency and brain activity: potential therapeutic application for the CNS. Curr. Pharm. Des. 6 (2000) 1287-1312
37. Czlonkowska A., Ciesielska A., Gromadzka G., and Kurkowska-Jastrzebska I. Gender differences in neurological disease: role of estrogens and cytokines. Endocrine 29 (2006) 243-256
38. D'Astous M., Mendez P., Morissette M., Garcia-Segura L.M., and Di Paolo T. Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Mol. Pharmacol. 69 (2006) 1492-1498
39. D'Astous M., Morissette M., and Di Paolo T. Effect of estrogen receptor agonists treatment in MPTP mice: evidence of neuroprotection by an ER alpha agonist. Neuropharmacology 47 (2004) 1180-1188
40. D'Astous M., Morissette M., Tanguay B., Callier S., and Di Paolo T. Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice. Synapse 47 (2003) 10-14
41. de Rijk M.C., Breteler M.M., Graveland G.A., Ott A., Grobbee D.E., van der Meche F.G., and Hofman A. Prevalence of Parkinson's disease in the elderly: the Rotterdam Study. Neurology 45 (1995) 2143-2146
42. Dhandapani K.M., and Brann D.W. Protective effects of estrogen and selective estrogen receptor modulators in the brain. Biol. Reprod. 67 (2002) 1379-1385
43. Di Paolo T. Modulation of brain dopamine transmission by sex steroids. Rev. Neurosci. 5 (1994) 27-41
44. Dluzen D.E. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice. Brain Res. 715 (1996) 113-118
45. Dluzen D.E., McDermott J.L., and Anderson L.I. Tamoxifen eliminates estrogen's neuroprotective effect upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system. Neurotox. Res. 3 (2001) 291-300
46. Dluzen D.E., McDermott J.L., and Liu B. Estrogen alters MPTP-induced neurotoxicity in female mice: effects on striatal dopamine concentrations and release. J. Neurochem. 66 (1996) 658-666
47. Dluzen D.E., McDermott J.L., and Liu B. Estrogen as a neuroprotectant against MPTP-induced neurotoxicity in C57/B1 mice. Neurotoxicol. Teratol. 18 (1996) 603-606
48. Dubal D.B., Rau S.W., Shughrue P.J., Zhu H., Yu J., Cashion A.B., Suzuki S., Gerhold L.M., Bottner M.B., Dubal S.B., Merchanthaler I., Kindy M.S., and Wise P.M. Differential modulation of estrogen receptors (ERs) in ischemic brain injury: a role for ERalpha in estradiol-mediated protection against delayed cell death. Endocrinology 147 (2006) 3076-3084
49. Ekue A., Boulanger J.F., Morissette M., and Di Paolo T. Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice. J. Neuroendocrinol. 14 (2002) 731-736
50. Enguita M., DeGregorio-Rocasolano N., Abad A., and Trullas R. Glycogen synthase kinase 3 activity mediates neuronal pentraxin 1 expression and cell death induced by potassium deprivation in cerebellar granule cells. Mol. Pharmacol. 67 (2005) 1237-1246
51. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., Vogel V., Robidoux A., Dimitrov N., Atkins J., Daly M., Wieand S., Tan-Chiu E., Ford L., and Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer. Inst. 90 (1998) 1371-1388
52. Fitzpatrick J.L., Mize A.L., Wade C.B., Harris J.A., Shapiro R.A., and Dorsa D.M. Estrogen-mediated neuroprotection against beta-amyloid toxicity requires expression of estrogen receptor alpha or beta and activation of the MAPK pathway. J. Neurochem. 82 (2002) 674-682
53. Fournier A., Berrino F., Riboli E., Avenel V., and Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Int. J. Cancer 114 (2005) 448-454
54. Gainetdinov R.R., Fumagalli F., Jones S.R., and Caron M.G. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J. Neurochem. 69 (1997) 1322-1325
55. Garcia-Segura L.M., Azcoitia I., and DonCarlos L.L. Neuroprotection by estradiol. Prog. Neurobiol. 63 (2001) 29-60
56. Garcia-Segura L.M., Cardona-Gomez G.P., Chowen J.A., and Azcoitia I. Insulin-like growth factor-I receptors and estrogen receptors interact in the promotion of neuronal survival and neuroprotection. J. Neurocytol. 29 (2000) 425-437
57. Gibson C.L., Gray L.J., Bath P.M., and Murphy S.P. Progesterone for the treatment of experimental brain injury; a systematic review. Brain 131 (2008) 318-328
58. Giladi N., and Honigman S. Hormones and Parkinson's disease. Neurology 45 (1995) 1028-1029
59. Goekoop R., Duschek E.J., Knol D.L., Barkhof F., Netelenbos C., Scheltens P., and Rombouts S.A. Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior. Neuroimage 25 (2005) 63-75
60. Goodenough S., Schleusner D., Pietrzik C., Skutella T., and Behl C. Glycogen synthase kinase 3beta links neuroprotection by 17beta-estradiol to key Alzheimer processes. Neuroscience 132 (2005) 581-589
61. Goodman Y., Bruce A.J., Cheng B., and Mattson M.P. Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J. Neurochem. 66 (1996) 1836-1844
62. Grandbois M., Morissette M., Callier S., and Di Paolo T. Ovarian steroids and raloxifene prevent MPTP-induced dopamine depletion in mice. Neuroreport 11 (2000) 343-346
63. Green S., Walter P., Kumar V., Krust A., Bornert J.M., Argos P., and Chambon P. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 320 (1986) 134-139
64. Growdon J.H., Kieburtz K., McDermott M.P., Panisset M., and Friedman J.H. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group. Neurology 50 (1998) 1327-1331
65. Gruber C.J., Tschugguel W., Schneeberger C., and Huber J.C. Production and actions of estrogens. N. Engl. J. Med. 346 (2002) 340-352
66. Guerra B., Diaz M., Alonso R., and Marin R. Plasma membrane oestrogen receptor mediates neuroprotection against beta-amyloid toxicity through activation of Raf-1/MEK/ERK cascade in septal-derived cholinergic SN56 cells. J. Neurochem. 91 (2004) 99-109
67. Hakansson A., Westberg L., Nilsson S., Buervenich S., Carmine A., Holmberg B., Sydow O., Olson L., Johnels B., Eriksson E., and Nissbrandt H. Interaction of polymorphisms in the genes encoding interleukin-6 and estrogen receptor beta on the susceptibility to Parkinson's disease. Am. J. Med. Genet. B. Neuropsychiatr. Genet. 133 (2005) 88-92
68. Hart L.L., and Davie J.R. The estrogen receptor: more than the average transcription factor. Biochem. Cell. Biol. 80 (2002) 335-341
69. Heikkila R.E., Hess A., and Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 224 (1984) 1451-1453
70. Heringa M. Review on raloxifene: profile of a selective estrogen receptor modulator. Int. J. Clin. Pharmacol. Ther. 41 (2003) 331-345
71. Hetman M., Cavanaugh J.E., Kimelman D., and Xia Z. Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J. Neurosci. 20 (2000) 2567-2574
72. Hornykiewicz O. The neurochemical basis of the pharmacology of Parkinson's disease. In: Calne D.B. (Ed). Handbook of Experimental Pharmacology. (1989), Springer-Verlag, New York 185-204
73. Jakowec M.W., and Petzinger G.M. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson's disease, with emphasis on mice and nonhuman primates. Comp. Med. 54 (2004) 497-513
74. Jourdain S., Morissette M., Morin N., and Di Paolo T. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. J. Neuroendocrinol. 17 (2005) 509-517
75. Kajta M., Budziszewska B., Marszal M., and Lason W. Effects of 17-beta estradiol and estriol on NMDA-induced toxicity and apoptosis in primary cultures of rat cortical neurons. J. Physiol. Pharmacol. 52 (2001) 437-446
76. Kajta M., and Lason W. Oestrogen effects on kainate-induced toxicity in primary cultures of rat cortical neurons. Acta Neurobiol. Exp. (Wars) 60 (2000) 365-369
77. Kajta M., Lason W., Bien E., and Marszal M. Neuroprotective effects of estrone on NMDA-induced toxicity in primary cultures of rat cortical neurons are independent of estrogen receptors. Pol. J. Pharmacol. 54 (2002) 727-729
78. Kalaitzidis D., and Gilmore T.D. Transcription factor cross-talk: the estrogen receptor and NF-kappaB. Trends Endocrinol. Metab. 16 (2005) 46-52
79. Kieburtz K., and Ravina B. Why hasn't neuroprotection worked in Parkinson's disease?. Nat. Clin. Pract. Neurol. 3 (2007) 240-241
80. Kilbourn M., and Frey K. Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains. Eur. J. Pharmacol. 307 (1996) 227-232
81. Kilbourn M.R., Kuszpit K., and Sherman P. Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse 35 (2000) 250-255
82. Kilbourn M.R., Sherman P., and Abbott L.C. Reduced MPTP neurotoxicity in striatum of the mutant mouse tottering. Synapse 30 (1998) 205-210
83. Kim C.J., Min Y.K., Ryu W.S., Kwak J.W., and Ryoo U.H. Effect of hormone replacement therapy on lipoprotein(a) and lipid levels in postmenopausal women. Influence of various progestogens and duration of therapy. Arch. Intern. Med. 156 (1996) 1693-1700
84. Kuiper G.G., Carlsson B., Grandien K., Enmark E., Haggblad J., Nilsson S., and Gustafsson J.A. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138 (1997) 863-870
85. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., and Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 5925-5930
86. Kumar V., and Chambon P. The estrogen receptor binds tightly to its responsive element as a ligand-induced homodimer. Cell 55 (1988) 145-156
87. Kuppers E., and Beyer C. Expression of estrogen receptor-alpha and beta mRNA in the developing and adult mouse striatum. Neurosci. Lett. 276 (1999) 95-98
88. Kuroki Y., Fukushima K., Kanda Y., Mizuno K., and Watanabe Y. Neuroprotection by estrogen via extracellular signal-regulated kinase against quinolinic acid-induced cell death in the rat hippocampus. Eur. J. Neurosci. 13 (2001) 472-476
89. Kurtzke J.F., and Goldberg I.D. Parkinsonism death rates by race, sex, and geography. Neurology 38 (1988) 1558-1561
90. Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M., and Webb P. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74 (2000) 311-317
91. Labrie F. Intracrinology. Mol. Cell. Endocrinol. 78 (1991) C113-118
92. Langston J.W., Ballard P., Tetrud J.W., and Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983) 979-980
93. Langston J.W., Forno L.S., Rebert C.S., and Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain. Res. 292 (1984) 390-394
94. Langston J.W., Langston E.B., and Irwin I. MPTP-induced parkinsonism in human and non-human primates-clinical and experimental aspects. Acta Neurol. Scand. Suppl. 100 (1984) 49-54
95. Levin E.R. Cellular functions of plasma membrane estrogen receptors. Steroids 67 (2002) 471-475
96. Li S.C., Schoenberg B.S., Wang C.C., Cheng X.M., Rui D.Y., Bolis C.L., and Schoenberg D.G. A prevalence survey of Parkinson's disease and other movement disorders in the People's Republic of China. Arch. Neurol. 42 (1985) 655-657
97. Lindberg M.K., Moverare S., Skrtic S., Gao H., Dahlman-Wright K., Gustafsson J.A., and Ohlsson C. Estrogen receptor (ER)-beta reduces ERalpha-regulated gene transcription, supporting a "ying yang" relationship between ERalpha and ERbeta in mice. Mol. Endocrinol. 17 (2003) 203-208
98. Lyons K.E., Hubble J.P., Troster A.I., Pahwa R., and Koller W.C. Gender differences in Parkinson's disease. Clin. Neuropharmacol. 21 (1998) 118-121
99. Mandel S.A., Sagi Y., and Amit T. Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurochem. Res. 32 (2007) 1694-1699
100. Maraganore D.M., Farrer M.J., McDonnell S.K., Elbaz A., Schaid D.J., Hardy J.A., and Rocca W.A. Case-control study of estrogen receptor gene polymorphisms in Parkinson's disease. Mov. Disord. 17 (2002) 509-512
101. Marder K., Tang M.X., Mejia H., Alfaro B., Cote L., Louis E., Groves J., and Mayeux R. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology 47 (1996) 155-160
102. Marin R., Guerra B., Alonso R., Ramirez C.M., and Diaz M. Estrogen activates classical and alternative mechanisms to orchestrate neuroprotection. Curr. Neurovasc. Res. 2 (2005) 287-301
103. Mattson M.P. Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 1 (2000) 120-129
104. Mayeux R., Denaro J., Hemenegildo N., Marder K., Tang M.X., Cote L.J., and Stern Y. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch. Neurol. 49 (1992) 492-497
105. Mensah-Nyagan A.G., Do-Rego J.L., Beaujean D., Luu-The V., Pelletier G., and Vaudry H. Neurosteroids: expression of steroidogenic enzymes and regulation of steroid biosynthesis in the central nervous system. Pharmacol. Rev. 51 (1999) 63-81
106. Mermelstein P.G., Becker J.B., and Surmeier D.J. Estradiol reduces calcium currents in rat neostriatal neurons via a membrane receptor. J. Neurosci. 16 (1996) 595-604
107. Mhyre A.J., and Dorsa D.M. Estrogen activates rapid signaling in the brain: role of estrogen receptor alpha and estrogen receptor beta in neurons and glia. Neuroscience 138 (2006) 851-858
108. Miller D.B., Ali S.F., O'Callaghan J.P., and Laws S.C. The impact of gender and estrogen on striatal dopaminergic neurotoxicity. Ann. N. Y. Acad. Sci. 844 (1998) 153-165
109. Miller G.W., Gainetdinov R.R., Levey A.I., and Caron M.G. Dopamine transporters and neuronal injury. Trends Pharmacol. Sci. 20 (1999) 424-429
110. Miller R.M., and Federoff H.J. Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems. Neuroscientist 11 (2005) 539-549
111. Miranda R., Sohrabji F., Singh M., and Toran-Allerand D. Nerve growth factor (NGF) regulation of estrogen receptors in explant cultures of the developing forebrain. J. Neurobiol. 31 (1996) 77-87
112. Mitra S.W., Hoskin E., Yudkovitz J., Pear L., Wilkinson H.A., Hayashi S., Pfaff D.W., Ogawa S., Rohrer S.P., Schaeffer J.M., McEwen B.S., and Alves S.E. Immunolocalization of estrogen receptor beta in the mouse brain: comparison with estrogen receptor alpha. Endocrinology 144 (2003) 2055-2067
113. Mize A.L., Shapiro R.A., and Dorsa D.M. Estrogen receptor-mediated neuroprotection from oxidative stress requires activation of the mitogen-activated protein kinase pathway. Endocrinology 144 (2003) 306-312
114. Mooradian A.D. Antioxidant properties of steroids. J. Steroid Biochem. Mol. Biol. 45 (1993) 509-511
115. Morales A.J., Nolan J.J., Nelson J.C., and Yen S.S. Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J. Clin. Endocrinol. Metab. 78 (1994) 1360-1367
116. Morissette M., Dicko A., Pezolet M., Callier S., and Di Paolo T. Effect of dehydroepiandrosterone and its sulfate and fatty acid ester derivatives on rat brain membranes. Steroids 64 (1999) 796-803
117. Morissette M., Jourdain S., Al Sweidi S., Menniti F.S., Ramirez A.D., and Di Paolo T. Role of estrogen receptors in neuroprotection by estradiol against MPTP toxicity. Neuropharmacology 52 (2007) 1509-1520
118. Morissette M., Le Saux M., D'Astous M., Jourdain S., Al Sweidi S., Morin N., Estrada-Camarena E., Mendez P., Garcia-Segura L.M., and Di Paolo T. Contribution of estrogen receptors alpha and beta to the effects of estradiol in the brain. J. Steroid. Biochem. Mol. Biol. 108 (2008) 327-338
119. Mutch W.J., Dingwall-Fordyce I., Downie A.W., Paterson J.G., and Roy S.K. Parkinson's disease in a Scottish city. Br. Med. J. (Clin. Res. Ed.) 292 (1986) 534-536
120. Myers R.E., Anderson L.I., and Dluzen D.E. Estrogen, but not testosterone, attenuates methamphetamine-evoked dopamine output from superfused striatal tissue of female and male mice. Neuropharmacology 44 (2003) 624-632
121. Nilsen J., and Brinton R.D. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 143 (2002) 205-212
122. Nilsen J., and Brinton R.D. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 10506-10511
123. O'Dowd B.F., Nguyen T., Marchese A., Cheng R., Lynch K.R., Heng H.H., Kolakowski Jr. L.F., and George S.R. Discovery of three novel G-protein-coupled receptor genes. Genomics 47 (1998) 310-313
124. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., and Scanlan T.S. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277 (1997) 1508-1510
125. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61 (2004) 561-566
126. Przedborski S., and Jackson-Lewis V. Mechanisms of MPTP toxicity. Mov. Disord. 13 (1998) 35-38
127. Quesada A., and Micevych P.E. Estrogen interacts with the IGF-1 system to protect nigrostriatal dopamine and maintain motoric behavior after 6-hydroxdopamine lesions. J. Neurosci. Res. 75 (2004) 107-116
128. Quesada A., Romeo H.E., and Micevych P. Distribution and localization patterns of estrogen receptor-beta and insulin-like growth factor-1 receptors in neurons and glial cells of the female rat substantia nigra: localization of ERbeta and IGF-1R in substantia nigra. J. Comp. Neurol. 503 (2007) 198-208
129. Ragonese P., D'Amelio M., Salemi G., Aridon P., Gammino M., Epifanio A., Morgante L., and Savettieri G. Risk of Parkinson disease in women: effect of reproductive characteristics. Neurology 62 (2004) 2010-2014
130. Ramirez A.D., Liu X., and Menniti F.S. Repeated estradiol treatment prevents MPTP-induced dopamine depletion in male mice. Neuroendocrinology 77 (2003) 223-231
131. Razandi M., Pedram A., Greene G.L., and Levin E.R. Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells. Mol. Endocrinol. 13 (1999) 307-319
132. Regan R.F., and Guo Y. Estrogens attenuate neuronal injury due to hemoglobin, chemical hypoxia, and excitatory amino acids in murine cortical cultures. Brain. Res. 764 (1997) 133-140
133. Rossouw J.E., Anderson G.L., Prentice R.L., LaCroix A.Z., Kooperberg C., Stefanick M.L., Jackson R.D., Beresford S.A., Howard B.V., Johnson K.C., Kotchen J.M., and Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
134. Rubin S.M. Parkinson's disease in women. Dis. Mon. 53 (2007) 206-213
135. Sagi Y., Mandel S., Amit T., and Youdim M.B. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis. 25 (2007) 35-44
136. Sampei K., Goto S., Alkayed N.J., Crain B.J., Korach K.S., Traystman R.J., Demas G.E., Nelson R.J., and Hurn P.D. Stroke in estrogen receptor-alpha-deficient mice. Stroke 31 (2000) 738-743 (discussion 744)
137. Sanchez R., Nguyen D., Rocha W., White J.H., and Mader S. Diversity in the mechanisms of gene regulation by estrogen receptors. Bioassays 24 (2002) 244-254
138. Saunders-Pullman R., Gordon-Elliott J., Parides M., Fahn S., Saunders H.R., and Bressman S. The effect of estrogen replacement on early Parkinson's disease. Neurology 52 (1999) 1417-1421
139. Sayeed I., Wali B., and Stein D.G. Progesterone inhibits ischemic brain injury in a rat model of permanent middle cerebral artery occlusion. Restor. Neurol. Neurosci. 25 (2007) 151-159
140. Schumacher M., Guennoun R., Ghoumari A., Massaad C., Robert F., El-Etr M., Akwa Y., Rajkowski K., and Baulieu E.E. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system. Endocr. Rev. 28 (2007) 387-439
141. Session D.R., Pearlstone M.M., Jewelewicz R., and Kelly A.C. Estrogens and Parkinson's disease. Med. Hypotheses 42 (1994) 280-282
142. Shelly W., Draper M.W., Krishnan V., Wong M., and Jaffe R.B. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet. Gynecol. Surv. 63 (2008) 163-181
143. Shimohama S., Sawada H., Kitamura Y., and Taniguchi T. Disease model: Parkinson's disease. Trends Mol. Med. 9 (2003) 360-365
144. Shughrue P.J. Estrogen attenuates the MPTP-induced loss of dopamine neurons from the mouse SNc despite a lack of estrogen receptors (ERalpha and ERbeta). Exp. Neurol. 190 (2004) 468-477
145. Shulman L.M., and Bhat V. Gender disparities in Parkinson's disease. Expert Rev. Neurother. 6 (2006) 407-416
146. Singer C.A., Figueroa-Masot X.A., Batchelor R.H., and Dorsa D.M. The mitogen-activated protein kinase pathway mediates estrogen neuroprotection after glutamate toxicity in primary cortical neurons. J. Neurosci. 19 (1999) 2455-2463
147. Smeyne R.J., and Jackson-Lewis V. The MPTP model of Parkinson's disease. Brain. Res. Mol. Brain Res. 134 (2005) 57-66
148. Son J.H., Chun H.S., Joh T.H., Cho S., Conti B., and Lee J.W. Neuroprotection and neuronal differentiation studies using substantia nigra dopaminergic cells derived from transgenic mouse embryos. J. Neurosci. 19 (1999) 10-20
149. Speciale S.G., Liang C.L., Sonsalla P.K., Edwards R.H., and German D.C. The neurotoxin 1-methyl-4-phenylpyridinium is sequestered within neurons that contain the vesicular monoamine transporter. Neuroscience 84 (1998) 1177-1185
150. Stein D.G. Brain damage, sex hormones and recovery: a new role for progesterone and estrogen?. Trends Neurosci. 24 (2001) 386-391
151. Stein D.G. The case for progesterone. Ann. N. Y. Acad. Sci. 1052 (2005) 152-169
152. Stein D.G., Wright D.W., and Kellermann A.L. Does progesterone have neuroprotective properties?. Ann. Emerg. Med. 51 (2008) 164-172
153. Strijks E., Kremer J.A., and Horstink M.W. Effects of female sex steroids on Parkinson's disease in postmenopausal women. Clin. Neuropharmacol. 22 (1999) 93-97
154. Sukovich D.A., Mukherjee R., and Benfield P.A. A novel, cell-type-specific mechanism for estrogen receptor-mediated gene activation in the absence of an estrogen-responsive element. Mol. Cell. Biol. 14 (1994) 7134-7143
155. Toran-Allerand C.D. Estrogen and the brain: beyond ER-alpha and ER-beta. Exp. Gerontol. 39 (2004) 1579-1586
156. Tsang K.L., Ho S.L., and Lo S.K. Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations. Neurology 54 (2000) 2292-2298
157. Tsukahara T., Takeda M., Shimohama S., Ohara O., and Hashimoto N. Effects of brain-derived neurotrophic factor on 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Neurosurgery 37 (1995) 733-739 (discussion 739-741)
158. Uhl G.R. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann. Neurol. 43 (1998) 555-560
159. Van Den Eeden S.K., Tanner C.M., Bernstein A.L., Fross R.D., Leimpeter A., Bloch D.A., and Nelson L.M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol. 157 (2003) 1015-1022
160. Vasudevan N., Kow L.M., and Pfaff D. Integration of steroid hormone initiated membrane action to genomic function in the brain. Steroids 70 (2005) 388-396
161. Vedder H., Teepker M., Fischer S., and Krieg J.C. Characterization of the neuroprotective effects of estrogens on hydrogen peroxide-induced cell death in hippocampal HT22 cells: time and dose-dependency. Exp. Clin. Endocrinol. Diab. 108 (2000) 120-127
162. Vogelvang T.E., van der Mooren M.J., Mijatovic V., and Kenemans P. Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women. Drugs 66 (2006) 191-221
163. Wade C.B., and Dorsa D.M. Estrogen activation of cyclic adenosine 5′-monophosphate response element-mediated transcription requires the extracellularly regulated kinase/mitogen-activated protein kinase pathway. Endocrinology 144 (2003) 832-838
164. Wade C.B., Robinson S., Shapiro R.A., and Dorsa D.M. Estrogen receptor (ER)alpha and ERbeta exhibit unique pharmacologic properties when coupled to activation of the mitogen-activated protein kinase pathway. Endocrinology 142 (2001) 2336-2342
165. Wagner G.C., Tekirian T.L., and Cheo C.T. Sexual differences in sensitivity to methamphetamine toxicity. J. Neural. Transm. Gen. Sect. 93 (1993) 67-70
166. Weatherman R.V., Clegg N.J., and Scanlan T.S. Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites. Chem. Biol. 8 (2001) 427-436
167. Westberg L., Hakansson A., Melke J., Shahabi H.N., Nilsson S., Buervenich S., Carmine A., Ahlberg J., Grundell M.B., Schulhof B., Klingborg K., Holmberg B., Sydow O., Olson L., Johnels E.B., Eriksson E., and Nissbrandt H. Association between the estrogen receptor beta gene and age of onset of Parkinson's disease. Psychoneuroendocrinology 29 (2004) 993-998
168. Wilson J.M., Levey A.I., Rajput A., Ang L., Guttman M., Shannak K., Niznik H.B., Hornykiewicz O., Pifl C., and Kish S.J. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47 (1996) 718-726
169. Wolf O.T., and Kirschbaum C. Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans. Brain. Res. Brain Res. Rev. 30 (1999) 264-288
170. Woodgett J.R. Molecular cloning and expression of glycogen synthase kinase-3/factor A. EMBO J. 9 (1990) 2431-2438
171. Wooten G.F., Currie L.J., Bovbjerg V.E., Lee J.K., and Patrie J. Are men at greater risk for Parkinson's disease than women?. J. Neurol. Neurosurg. Psychiatry 75 (2004) 637-639
172. Wright D.W., Kellermann A.L., Hertzberg V.S., Clark P.L., Frankel M., Goldstein F.C., Salomone J.P., Dent L.L., Harris O.A., Ander D.S., Lowery D.W., Patel M.M., Denson D.D., Gordon A.B., Wald M.M., Gupta S., Hoffman S.W., and Stein D.G. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann. Emerg. Med. 49 (2007) 391-402 (402, e391-392)
173. Wu X., Glinn M.A., Ostrowski N.L., Su Y., Ni B., Cole H.W., Bryant H.U., and Paul S.M. Raloxifene and estradiol benzoate both fully restore hippocampal choline acetyltransferase activity in ovariectomized rats. Brain Res. 847 (1999) 98-104
174. Xu K., Xu Y., Brown-Jermyn D., Chen J.F., Ascherio A., Dluzen D.E., and Schwarzschild M.A. Estrogen prevents neuroprotection by caffeine in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. J. Neurosci. 26 (2006) 535-541
175. Yaffe K., Krueger K., Cummings S.R., Blackwell T., Henderson V.W., Sarkar S., Ensrud K., and Grady D. Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the multiple outcomes of raloxifene evaluation (MORE) randomized trial. Am. J. Psychiatry 162 (2005) 683-690
176. Yu L., and Liao P.C. Estrogen and progesterone distinctively modulate methamphetamine-induced dopamine and serotonin depletions in C57BL/6J mice. J. Neural Transm. 107 (2000) 1139-1147
177. Zappia M., Annesi G., Nicoletti G., Arabia G., Annesi F., Messina D., Pugliese P., Spadafora P., Tarantino P., Carrideo S., Civitelli D., De Marco E.V., Ciro-Candiano I.C., Gambardella A., and Quattrone A. Sex differences in clinical and genetic determinants of levodopa peak-dose dyskinesias in Parkinson disease: an exploratory study. Arch. Neurol. 62 (2005) 601-605
178. Zhang H.T., Li L.Y., Zou X.L., Song X.B., Hu Y.L., Feng Z.T., and Wang T.T. Immunohistochemical distribution of NGF, BDNF, NT-3, and NT-4 in adult rhesus monkey brains. J. Histochem. Cytochem. 55 (2007) 1-19
179. Zhao L., O'Neill K., and Diaz Brinton R. Selective estrogen receptor modulators (SERMs) for the brain: current status and remaining challenges for developing NeuroSERMs. Brain Res. Brain Res. Rev. 49 (2005) 472-493